Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Differentiated Thyroid Cancer (DTC)
Conditions
Differentiated Thyroid Cancer (DTC)
Trial Timeline
Nov 15, 2021 → Jun 4, 2027
NCT ID
NCT04940052About Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo
Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo is a phase 3 stage product being developed by Novartis for Differentiated Thyroid Cancer (DTC). The current trial status is active. This product is registered under clinical trial identifier NCT04940052. Target conditions include Differentiated Thyroid Cancer (DTC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04940052 | Phase 3 | Active |
Competing Products
20 competing products in Differentiated Thyroid Cancer (DTC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 33 |
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| Selpercatinib Monotherapy | Eli Lilly | Phase 2 | 52 |
| Selumetinib + Placebo + Radioactive Iodine Therapy | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + Cisplatin + Docetaxel + Carboplatin | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 23 |
| Everolimus + Sorafenib | Novartis | Phase 2 | 52 |
| PDR001 | Novartis | Phase 2 | 52 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 51 |
| sunitinib | Pfizer | Approved | 84 |
| Vandetanib (SAR390530) + Placebo | Sanofi | Phase 3 | 76 |
| Thyrogen (thyrotropin alfa for injection) | Sanofi | Phase 3 | 76 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Larotrectinib monotherapy | Bayer | Phase 2 | 49 |